<DOC>
	<DOCNO>NCT00851344</DOCNO>
	<brief_summary>A randomised , double-blind , placebo-controlled , 4-period incomplete block crossover study single oral dose GSK835726 ( 100mg , 50mg , 10mg ) , Cetirizine ( 10mg ) placebo evaluate efficacy safety use Environmental challenge chamber male subject seasonal allergic rhinitis</brief_summary>
	<brief_title>Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Subject healthy apart seasonal allergic rhinitis , determine physician . Can mild asthma . Male Aged 18 60 Weight 50kg+ , BMI 1932 kg/m2 Exhibit response Challenge Chamber skin prick test . Nonsmoker Capable give informed consent No nasal structural abnornmality/polyposis , surgery , infection . respiratory disease , mild asthma seasonal allergic rhinitis participate another clinical study within 30 day . Subject donate unit blood within 1 month Use prescription nonprescription drug , include vitamin st john 's wort within 7 day trial . History sensitivty drug History alcohol/drug abuse within 12 month . Positive Hepatitis B antibody test Positive HIV antibody test Risk noncompliance study protocol Perenial allergic rhinitis Administration oral , injectable dermal corticosteriods within 8 week , intranasal inhale within 3 week . Past present disease may affect outcome , judge investigator Specific Immunotherapy within 2 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Proof-of-Concept</keyword>
	<keyword>Allergic Rhinitis</keyword>
</DOC>